Skip to main content
SpringerLink
Log in

Role of Systemic Therapy

  • Chapter
Multimodality Management of Borderline Resectable Pancreatic Cancer

  • 865 Accesses

Abstract

Management of resectable and borderline resectable pancreatic adenocarcinoma (BRPC) represents a significant challenge. Unfortunately, in most patients, PDAC is a systemic disease at presentation. Even in the presence of excellent perioperative supportive care and low mortality in high-volume centers, approximately 80 % of patients who undergo resection will develop metastases and die of their disease within 5 years [1, 2]. This is because most patients likely have micrometastatic disease at the time of attempted curative resection [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Yeo CJ, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225(5):621–33. discussion 633-6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Li D, et al. Pancreatic cancer. Lancet. 2004;363(9414):1049–57.

    Article  CAS  PubMed  Google Scholar 

  3. Smeenk HG, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 2007;246(5):734–40.

    Article  PubMed  Google Scholar 

  4. Katz MH, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(4):836–47.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Neoptolemos JP, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758–68.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Wright JC. Update in cancer chemotherapy: gastrointestinal cancer, cancer of the pancreas. J Natl Med Assoc. 1986;78(6):519–27.

    PubMed Central  CAS  PubMed  Google Scholar 

  7. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903.

    Article  CAS  PubMed  Google Scholar 

  8. Klinkenbijl JH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82. discussion 782-4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Neoptolemos JP, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–85.

    Article  CAS  PubMed  Google Scholar 

  10. Neoptolemos JP, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10.

    Article  CAS  PubMed  Google Scholar 

  11. Oettle H, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.

    Article  CAS  PubMed  Google Scholar 

  12. Oettle H, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.

    Article  CAS  PubMed  Google Scholar 

  13. Spitz FR, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15(3):928–37.

    CAS  PubMed  Google Scholar 

  14. Ishikawa O, et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple’s procedure for adenocarcinoma of the pancreatic head? Arch Surg. 1994;129(10):1075–80.

    Article  CAS  PubMed  Google Scholar 

  15. Coia L, et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys. 1994;30(1):161–7.

    Article  CAS  PubMed  Google Scholar 

  16. Weese JL, et al. Increased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapy. Int J Pancreatol. 1990;7(1–3):177–85.

    CAS  PubMed  Google Scholar 

  17. Lu DS, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol. 1997;168(6):1439–43.

    Article  CAS  PubMed  Google Scholar 

  18. Tamm EP, et al. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging. 2006;31(5):568–74.

    Article  CAS  PubMed  Google Scholar 

  19. Kaneko OF, et al. Performance of multidetector computed tomographic angiography in determining surgical resectability of pancreatic head adenocarcinoma. J Comput Assist Tomogr. 2010;34(5):732–8.

    Article  PubMed  Google Scholar 

  20. Tran Cao HS, et al. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014;18(2):269–78. discussion 278.

    Article  PubMed  Google Scholar 

  21. Mehta VK, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2001;5(1):27–35.

    Article  CAS  PubMed  Google Scholar 

  22. Varadhachary GR, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035–46.

    Article  PubMed  Google Scholar 

  23. Katz MH, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749–56.

    Article  PubMed  Google Scholar 

  24. Chun YS, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol. 2010;17(11):2832–8.

    Article  PubMed  Google Scholar 

  25. Stokes JB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18(3):619–27.

    Article  PubMed  Google Scholar 

  26. Chuong MD, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013;86(3):516–22.

    Article  PubMed  Google Scholar 

  27. Ducreux M, et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol. 2004;15(3):467–73.

    Article  CAS  PubMed  Google Scholar 

  28. Ueno H, et al. A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2007;59(4):447–54.

    Article  CAS  PubMed  Google Scholar 

  29. Conroy T, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer—a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 2005;23(6):1228–36.

    Article  CAS  PubMed  Google Scholar 

  30. Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    Article  CAS  PubMed  Google Scholar 

  31. Paniccia A, et al. Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study. Medicine (Baltimore). 2014;93(27), e198.

    Article  CAS  Google Scholar 

  32. Blazer M, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22(4):1153–9.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Sahora K, et al. NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery. 2011;149(3):311–20.

    Article  PubMed  Google Scholar 

  34. Sahora K, et al. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg. 2011;35(7):1580–9.

    Article  PubMed  Google Scholar 

  35. Lee JL, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 2012;152(5):851–62.

    Article  PubMed  Google Scholar 

  36. White RR, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol. 2001;8(10):758–65.

    Article  CAS  PubMed  Google Scholar 

  37. Le Scodan R, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol. 2009;20(8):1387–96.

    Article  PubMed  Google Scholar 

  38. Evans DB, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3496–502.

    Article  CAS  PubMed  Google Scholar 

  39. Talamonti MS, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13(2):150–8.

    Article  PubMed  Google Scholar 

  40. Takahashi H, et al. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg. 2013;258(6):1040–50.

    Article  PubMed  Google Scholar 

  41. Gillen S, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4), e1000267.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  42. Ueno H, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31(13):1640–8.

    Article  CAS  PubMed  Google Scholar 

  43. Uesaka K, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol. 2013; 31(4): abstr 145.

    Google Scholar 

  44. Fukutomi A, et al. JASPAC 01: randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol. 2013; 31(15): abstr 4008.

    Google Scholar 

  45. Mizuma M, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: a prospective, multi-institutional, phase II trial. J Clin Oncol. 2014; 32(3): abstr 283.

    Google Scholar 

  46. Hattori M, et al. Neoadjuvant chemoradiotherapy with S-1 in patients with borderline resectable pancreatic cancer. J Clin Oncol. 2014; 32(3): abstr 302.

    Google Scholar 

  47. Sudo K, Nakamura K, Yamaguchi T. S-1 in the treatment of pancreatic cancer. World J Gastroenterol. 2014;20(41):15110–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Von Hoff DD, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29(34):4548–54.

    Article  CAS  Google Scholar 

  49. Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

    Article  CAS  Google Scholar 

  50. Olowokure O, Torregroza-Sanchez MP, Bedoya-Apraez ID. Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC). J Gastrointest Oncol. 2013;4(2):E16–8.

    PubMed Central  PubMed  Google Scholar 

  51. Sanford DE, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res. 2013;19(13):3404–15.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Wang-Gillam A, et al. Phase IB study of FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma (PC). J Clin Oncol. 2015;33(3 suppl):abstr 338.

    Google Scholar 

  53. Montgomery RC, et al. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol. 1997;4(7):551–6.

    Article  CAS  PubMed  Google Scholar 

  54. Distler M, et al. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas—a retrospective tumor marker prognostic study. Int J Surg. 2013;11(10):1067–72.

    Article  PubMed  Google Scholar 

  55. Tzeng CW, et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014;16(5):430–8.

    Article  PubMed Central  Google Scholar 

  56. Katz MH, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17(7):1794–801.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Wasan SM, et al. Use of expandable metallic biliary stents in resectable pancreatic cancer. Am J Gastroenterol. 2005;100(9):2056–61.

    Article  PubMed  Google Scholar 

  58. Boulay BR, Gardner TB, Gordon SR. Occlusion rate and complications of plastic biliary stent placement in patients undergoing neoadjuvant chemoradiotherapy for pancreatic cancer with malignant biliary obstruction. J Clin Gastroenterol. 2010;44(6):452–5.

    CAS  PubMed  Google Scholar 

  59. Boulay BR, Parepally M. Managing malignant biliary obstruction in pancreas cancer: choosing the appropriate strategy. World J Gastroenterol. 2014;20(28):9345–53.

    PubMed Central  PubMed  Google Scholar 

  60. Silver JK, Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil. 2013;92(8):715–27.

    Article  PubMed  Google Scholar 

  61. Li C, et al. Impact of a trimodal prehabilitation program on functional recovery after colorectal cancer surgery: a pilot study. Surg Endosc. 2013;27(4):1072–82.

    Article  PubMed  Google Scholar 

  62. Mayo NE, et al. Impact of preoperative change in physical function on postoperative recovery: argument supporting prehabilitation for colorectal surgery. Surgery. 2011;150(3):505–14.

    Article  PubMed  Google Scholar 

  63. de Paleville DT, Topp RV, Swank AM. Effects of aerobic training prior to and during chemotherapy in a breast cancer patient: a case study. J Strength Cond Res. 2007;21(2):635–7.

    PubMed  Google Scholar 

  64. Tzeng CW, et al. Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. J Gastrointest Surg. 2014;18(1):146–55. discussion 155–6.

    Article  PubMed  Google Scholar 

  65. Cassinotto C, et al. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Radiology. 2014;273(1):108–16.

    Article  PubMed  Google Scholar 

  66. Nordh S, Ansari D, Andersson R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. World J Gastroenterol. 2014;20(26):8482–90.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  67. Lee Y, et al. Human equilibrative nucleoside transporter-1 knockdown tunes cellular mechanics through epithelial-mesenchymal transition in pancreatic cancer cells. PLoS One. 2014;9(10), e107973.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  68. Poplin E, et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol. 2013;31(35):4453–61.

    Article  CAS  PubMed  Google Scholar 

  69. Infante JR, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007;25(3):319–25.

    Article  PubMed  Google Scholar 

  70. Sinn M, et al. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol. 2014;25(5):1025–32.

    Article  CAS  PubMed  Google Scholar 

  71. Alvarez R, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 2013;109(4):926–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Hidalgo M, et al. O-0004 SPARC analysis in the phase III MPACT trial of nab-paclitaxel (nab-p) plus gemcitabine (gem) vs gem alone for patients with metastatic pancreatic cancer (PC). Ann Oncol. 2014;25 suppl 2:ii106.

    Article  Google Scholar 

  73. Javle M, et al. Biomarkers of TGF-beta signaling pathway and prognosis of pancreatic cancer. PLoS One. 2014;9(1):e85942.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  74. Hua Z, et al. Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World J Gastroenterol. 2003;9(12):2764–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Du Y, et al. Meta-analysis of the prognostic value of smad4 immunohistochemistry in various cancers. PLoS One. 2014;9(10):e110182.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  76. Boone BA, et al. Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer. J Surg Oncol. 2014;110(2):171–5.

    Article  PubMed  Google Scholar 

  77. Bobek V, et al. Circulating tumor cells in pancreatic cancer patients: enrichment and cultivation. World J Gastroenterol. 2014;20(45):17163–70.

    Article  PubMed Central  PubMed  Google Scholar 

  78. Kulemann B, et al. Circulating tumor cells found in patients with localized and advanced pancreatic cancer. Pancreas. 2015;44(4):547–50.

    Article  CAS  PubMed  Google Scholar 

  79. Sikora K, et al. Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. Int J Biol Markers. 2015;30(1):e136–41.

    Article  PubMed  Google Scholar 

  80. Gerstenhaber F, et al. Pancreaticoduodenectomy in elderly adults: is it justified in terms of mortality, long-term morbidity, and quality of life? J Am Geriatr Soc. 2013;61(8):1351–7.

    Article  PubMed  Google Scholar 

  81. Frakes JM, et al. Resected pancreatic cancer outcomes in the elderly. J Geriatr Oncol. 2015;6:127–32.

    Article  PubMed  Google Scholar 

  82. Makary MA, et al. Pancreaticoduodenectomy in the very elderly. J Gastrointest Surg. 2006;10(3):347–56.

    Article  PubMed  Google Scholar 

  83. Miura JT, et al. Neoadjuvant therapy for pancreatic cancer in patients older than age 75. J Clin Oncol. 2014;32(3):abstr 287.

    Google Scholar 

  84. Son CO, et al. Outcomes of neoadjuvant chemotherapy with FOLFOX/FOLFIRINOX and chemoradiotherapy in borderline resectable pancreatic cancer: single-institution experience. J Clin Oncol. 2014; 32(3): abstr 327.

    Google Scholar 

  85. Turrini O, et al. Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma. Eur J Surg Oncol. 2009;35(12):1306–11.

    Article  CAS  PubMed  Google Scholar 

  86. Barugola G, et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012;203(2):132–9.

    Article  PubMed  Google Scholar 

  87. Kang CM, et al. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg. 2012;16(3):509–17.

    Article  PubMed  Google Scholar 

  88. Kharofa J, et al. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Radiother Oncol. 2014;113(1):41–6.

    Article  PubMed Central  PubMed  Google Scholar 

  89. Landry J, et al. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010;101(7):587–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  90. Pipas JM, et al. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Ann Oncol. 2012;23(11):2820–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  91. Kim EJ, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013;119(15):2692–700.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  92. Motoi F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013;20(12):3794–801.

    Article  PubMed  Google Scholar 

  93. Rose JB, et al. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol. 2014;21(5):1530–7.

    Article  PubMed  Google Scholar 

  94. Takeda Y, et al. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma. Jpn J Clin Oncol. 2014;44(12):1172–80.

    Article  PubMed  Google Scholar 

  95. Esnaola NF, et al. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014;88(4):837–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Medicine, MD Anderson Cancer Center, 1400 Holcombe Blvd, Unit 463, Houston, TX, 77030, USA

    Matthew J. Reilley

  2. Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX, 77030, USA

    Gauri R. Varadhachary

Authors
  1. Matthew J. Reilley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gauri R. Varadhachary
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gauri R. Varadhachary .

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas, USA

    Matthew H.G. Katz

  2. Division of Surgical Oncology, The University of Cincinnati Medical Center, Cincinnati, Ohio, USA

    Syed A. Ahmad

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Reilley, M.J., Varadhachary, G.R. (2016). Role of Systemic Therapy. In: Katz, M., Ahmad, S. (eds) Multimodality Management of Borderline Resectable Pancreatic Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-22780-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22780-1_6

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22779-5

  • Online ISBN: 978-3-319-22780-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation